Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Aetna CEO Urges Debate on What ‘Single-Payer’ Healthcare Would Be

Reuters Staff  |  May 15, 2017

NEW YORK (Reuters)—Aetna Inc, Chief Executive Officer Mark Bertolini wants a debate about what a single-payer healthcare system in the U.S would look like, but says he does not think the federal government should run it. “I think government-run healthcare would be a bad idea,” Bertolini says during an investor conference on Frida. The government’s…

Lifetime Risk of Hand Arthritis May Be More Than 40%

Madeline Kennedy  |  May 12, 2017

(Reuters Health)—A new study finds that as many as four in 10 people may develop hand osteoarthritis. Among women, researchers found the lifetime risk was 47% while for men it was about 25%. Obese people also had 11% higher lifetime risk than those who were not obese. Hand osteoarthritis can cause disability and problems with…

English Hospitals Divert Ambulances After Ransomware Cyber Attack

Costas Pitas & Alistair Smout  |  May 12, 2017

LONDON (Reuters)—Hospitals and doctors’ surgeries across England were forced to turn away patients and cancel appointments on Friday after a nationwide ‘ransomware’ cyber attack crippled some computer systems in the state-run health service. The U.K. National Health Service (NHS) said 16 organizations had been affected by the cyber attack but said it had not been…

Johnson & Johnson Discloses U.S. Probe Related to Arthritis Drugs

Reuters Staff  |  May 12, 2017

(Reuters) – Healthcare conglomerate Johnson & Johnson said on Monday the U.S. Department of Justice (DOJ) has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs. The U.S. healthcare company said its Janssen Biotech Inc. unit received a civil investigative demand from the DOJ…

Pembrolizumab May Induce Sarcoid-Like Skin Reactions

Marilynn Larkin  |  May 12, 2017

NEW YORK (Reuters Health)—Eruptive keatoacanthomas and extensive panniculitus are among the dermatological conditions associated with the anticancer agent pembrolizumab, researchers say. Pembrolizumab, a humanized IgG4 PD-1 (programmed cell death-1) antagonist antibody, is an immune checkpoint inhibitor (CPI) approved in the U.S. for treating advanced melanoma, non-small-cell lung cancer and head and neck squamous cell carcinoma….

How Gout Patients Can Stay on Target with the Go for Six Campaign

Karen Appold  |  May 12, 2017

Gout patients need to lower their uric acid levels to 6.0 mg/dL or below and maintain that level. According to N. Lawrence Edwards, MD, MACP, MACR, an education campaign has been raising awareness of this fact and helping gout patients…

Aetna Fully Exits Obamacare Exchanges with Pull-Out in 2 States

Deena Beasley  |  May 11, 2017

(Reuters)—Health insurer Aetna Inc said on Wednesday it will exit the 2018 Obamacare individual insurance market in Delaware and Nebraska – the two remaining states where it offered the plans. Aetna had already said it would exit the individual commercial market in Virginia and Iowa, after pulling out of several other states last year. Aetna…

Cracking, Popping Joints May Foretell Arthritis

Carolyn Crist  |  May 11, 2017

(Reuters Health)—Grating, cracking or popping sounds around joints may predict future arthritis, especially in the knees, according to a recent U.S. study. Among thousands of people with no knee pain who were followed for three years, one quarter had noisy knees yet they made up three quarters of the cases of symptomatic knee arthritis that…

Pricey Arthritis Drug Effective in Small Fraction of Ulcerative Colitis Cases

Gene Emery  |  May 9, 2017

NEW YORK (Reuters Health)—Pfizer’s expensive arthritis drug tofacitinib has been shown to produce a remission in nearly 1 in 5 patients with moderate to severe ulcerative colitis, but long-term remission persists in fewer than half of those cases. In a series of studies published in the May 4 New England Journal of Medicine, researchers reported…

U.S. Democrats Criticize Senate’s All-Male Healthcare Group

John Whitesides & Sarah N. Lynch  |  May 9, 2017

WASHINGTON (Reuters)—U.S. Democrats on Sunday criticized the lack of women on a working group in the Republican-led Senate that will craft a plan to pass legislation to repeal and replace Obamacare. As the Senate begins to wrestle with a Republican healthcare bill narrowly approved by the House of Representatives last week, senators questioned why the…

  • « Previous Page
  • 1
  • …
  • 429
  • 430
  • 431
  • 432
  • 433
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences